Abstract
Abstract Introduction: The combination of cholangiocarcinoma and hepatocellular carcinoma is a rare entity. Methods: We will present a clinical case involving a combination of cholangiocarcinoma and hepatocellular carcinoma in a patient with post-viral C cirrhosis. Results: A 60 Y.O male know with a personal history of hepatitis treated in 1969 by an unknown injectable treatment for two years, was presented at the consultation for evolving abdominal bloating. CT-scan revealed ascites with a total portal vein thrombosis and a heterogeneous tumor occupying the right liver without “wash-out” sign. The patient was put under anticoagulation with LMWH. After a week, liver MRI found that the ascites has totally dried, the thrombosis disappeared, and revealed that the tumor had a typical aspect of cholangiocarcinoma. Alfa-fetal protein test was to 1156 IU / ml. Liver biopsy was contradictory; on some pieces hepatocellular carcinoma was found and on others cholangiocarcinoma. Because Sorafenib is a multikinase inhibitor with anti-angiogenic and anti-proliferative action it can be effective on many tumors as they use the same ligands and signaling pathways similar to proliferate, it was chosen instead of chemotherapy at 400 mg/day. Sure enough, after two weeks of treatment, alfa fetoprotein decreased to 834 IU/ml and after two months biology and imaging found a satisfactory partial response. Currently, after six months of treatment, the patient is in complete clinical, biological and radiological remission except that the treatment cannot be interrupted for the time. Surgeons are discussing a partial surgery to the residual liver retraction. Conclusion: This association is rare and needs deep research especially molecular testing for patients who have a spectacular response. Citation Format: Khaoula Mazouzi. Association of cholangiocarcinoma and hepatocellular carcinoma: Which one should be treated? [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr B01.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
